Biomatics Capital Closes $200 Million Fund; Investments Focus on Genomics and Digital Health
SEATTLE, March 15, 2017 /PRNewswire/ -- Biomatics Capital Partners, a venture capital firm investing in transformational innovation at the intersection of health care and technology, has announced the closing of its initiatory fund of $200 million, in excess of the fund target of $150 million. Investors include a dynamic mix of family offices, institutions and individuals.
Biomatics focuses on advancing academic research and early-stage health care innovation to commercialization, with investments concentrated in areas of genomics, digital health and data-driven health care technologies.
The Biomatics team is led by Managing Directors Boris Nikolic, M.D. and Julie Sunderland, who have invested together in emerging technology, health care and life science ventures since 2010. They combine scientific and financial expertise with an established network of leading academics, pharma executives and venture capital firms. Once invested, they take an active role with portfolio companies, supporting startups with hiring, intellectual property, regulatory issues and exit strategy.
"Our health care ecosystem is at a tipping point," said Dr. Nikolic, who previously served as chief advisor for science and technology to Bill Gates. "In the next decade, breakthrough science and technology will fundamentally transform the practice of medicine and delivery of health care. Data will drive this transformation."
Biomatics estimates that it will invest in 15-20 companies through this fund, acting as Series A lead investor in a majority of the deals. Initial investments typically range from $5 million to $10 million, with up to $20 million over the life of the investment.
"It's our goal to seek out radically innovative solutionsthe outliers," Ms. Sunderland added. Prior to co-founding Biomatics with Dr. Nikolic in 2016, she was director of Program Related Investments for the Bill & Melinda Gates Foundation. "By combining the best of science with sound investment practices, we are looking to create extraordinary financial value for our investors and a pathway to better patient outcomes."
Biomatics' current portfolio includes: AiCure (medication adherence powered by artificial intelligence), Aledade (data-driven business model for accountable health care), BlackThorn Therapeutics (informatics-driven drug discovery), Blue Talon (enterprise-level data security for health care), Denali Therapeutics (next-gen therapeutics for neurodegenerative diseases), GRAIL (genomics-based cancer screening), Omniome (low-cost DNA sequencing platform) and Twist Bioscience (synthetic DNA).
About Biomatics Capital Biomatics Capital invests in transformational innovation at the intersection of healthcare and technology. Based in Seattle, Biomatics is a $200 million fund that focuses on early-stage investments, primarily in genomics and digital health. Co-founders and General Partners Dr. Boris Nikolic and Julie Sunderland have invested together in emerging technology, health care and life science ventures since 2010, leveraging their deep technical knowledge and partnering expertise with an established network of leading academics, pharma executives and venture capital firms. For more information, please visit www.biomaticscapital.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biomatics-capital-closes-200-million-fund-investments-focus-on-genomics-and-digital-health-300423740.html
SOURCE Biomatics Capital